Cisplatin: continuous versus bolus.
Gratton
Michael Anne
MA
Auditory Research Lab, Department of Otorhinolaryngology-Head Neck Surgery, University of Pennsylvania, Philadelphia, PA, USA. grattonm@mail.med.upenn.edu
Smyth
Brendan J
BJ
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics; D002648:Child; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics; D018240:Endodermal Sinus Tumor / Q000150:complications / Q000188:drug therapy; D006207:Half-Life; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced / Q000517:prevention & control*; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D009373:Neoplasms, Germ Cell and Embryonal / Q000150:complications / Q000188:drug therapy; D011485:Protein Binding; D012189:Retrospective Studies
D000970:Antineoplastic Agents; D002945:Cisplatin